Omada's Record Quarter May Only Reset the Debate-Stock Still Looks About 4% Undervalued

Omada's record Q2 improved the story, but Investor Day is the real test

Omada just showed it can post a standout quarter, but the stock still trades as if investors are waiting for more proof. It was last closing at $23.67 after a sharp recent move, yet it still carries a trailing P/E Ratio of 473.40. Even after the beat, that remains an expensive setup for a business that still needs to show the latest quarter was the start of a trend, not a one-off.

That is why the next few weeks matter more than the quarter itself. Omada has scheduled its first Investor Day on September 10, 2026, a half-day, in-person event in New York City that begins at 1:00 PM EDT. This is the near-term catalyst that can translate a strong Q2 into a clearer case for how durable the growth is and what kind of multiple the market should assign.

• The earnings move already reflected some optimism.
• September 10 will test whether that optimism is supported by a credible long-term plan.
• The next repricing should depend more on management's visibility and guidance than on a single record quarter.

Q2 matters because profitability and scale improved together

The key shift is not just the headline beat. It is that Q2 began to answer the main operating critique: Omada is no longer just a growth story searching for profitability. The company posted Q2 revenue of $88 million, gross margin of 73%, net income of $5 million, and adjusted EBITDA of $11 million. It also reached approximately 1.1 million total members. That combination matters because investors usually pay up when they see scale, margins, and platform depth moving in the same direction.

Margin expansion makes the growth more credible

The most important detail was not only that revenue grew, but that the business also became more efficient. Gross margin rose to 73% in Q2 from 66% in Q2 2025, while total members increased 45% year over year. That is an important signal. Many virtual-care models scale by adding staff, which can keep margins flat. Omada's margin improvement suggests the operating model may be starting to leverage as it gets bigger.

The profit turn reinforces the point. The company moved from a net loss of $5 million in Q2 2025 to net income of $5 million in the second quarter, and from an adjusted EBITDA loss of $0.2 million in Q2 2025 to adjusted EBITDA of $11 million in the second quarter. One quarter does not prove durability, but it does make the old argument that Omada could grow without profiting much harder to defend.

The growth story now looks broader than one product or one channel

Q1 had already set up a stronger backdrop. Revenue had grown 42% year over year and members had surpassed one million, reaching 1.02 million total members. Q2 then built on that momentum, with membership up 45% year over year. Management also said diabetes and hypertension enrollment were growing faster than legacy programs, and the company added its first cholesterol management deployment.

That breadth matters. It is easy to over-attribute a rebound to a single tailwind, but the evidence now points to a broader engine: more conditions, more access pathways, and a better margin structure than the market may have credited.

What investors should watch next

Investors should still avoid anchoring on one record quarter. Recency bias can make a staging point look like a new baseline. The better test is whether these operating trends continue into the next report and whether management makes the driver mix clearer at its first Investor Day on September 10, 2026.

Watch three things:

• Does gross margin stay in the low-70% range, or was Q2 an outlier?
• Does member growth remain strong after passing 1 million, or slow meaningfully?
• Does profitability expand from here, or look dependent on one unusually good quarter?

If those answers stay constructive, the market will have less reason to dismiss Omada's latest quarter as a temporary rebound.